Primary Cell Culture Market Size, Share, and Trends 2024 to 2033

Primary Cell Culture Market (By Product: Primary Cell, Reagents, Supplements, Media; By Application: Vaccine Production, Stem Cell Therapy, Cancer Research; By Cell Type: Animal Cells, Human Cells) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : April 2024
  • Report Code : 3010
  • Category : Healthcare

Primary Cell Culture Market Size to Reach USD 21.51 Bn by 2033

The global primary cell culture market size was estimated at USD 7.03 billion in 2023 and it is projected to hit around USD 21.51 billion by 2033, expanding at a CAGR of 11.81% during the forecast period 2024 to 2033.

Primary Cell Culture Market Size 2024 to 2033

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Primary Cell Culture Market Key Takeaways

  • By Product, the primary cell culture segment captured more than 36% of revenue share in 2023.
  • By Application, the vaccine production segment dominated the global market in 2023.
  • By Cell Type, the animal cells segment contributed more than 61% of revenue share in 2023.
  • North America generated more than 52.14% of revenue share in 2023 and is anticipated to keep this position between 2024 to 2033.

Primary Cell Culture Market Size in the U.S. 2024 to 2033

The U.S. primary cell culture market size reached USD 4.93 billion in 2023 and is anticipated to be worth around USD 15.38 billion by 2033, poised to grow at a CAGR of 12.02% from 2024 to 2033.

U.S. Primary Cell Culture Market Size 2024 to 2033

North America held the largest share of 52.14% in 2023 and is anticipated to keep this position during the forecast period. The growth of the region is driven by factors such as the high cost of healthcare, the increasing prevalence of chronic diseases, an aging population, and government funding support. Market players' focus on developing innovative cell culture applications, the availability of diverse cell types, and their interactions also contribute to the expansion of the market in the region.

Primary Cell Culture Market Share, By Region, 2023 (%)

Meanwhile, the Asia Pacific region is projected to experience the fastest growth over the forecast period. This growth is primarily attributed to decreased costs of stem cell transplantation, which drives strong demand in the region. Additionally, significant research and development activities conducted by scientists in the area contribute to its expansion. For example, in March 2020, researchers at China's Centre for Disease Control (CDC) successfully cultured SARS-CoV-2 by means of lung airway cells grown in human tissue culture systems.

Primary Cell Culture Market Size in Europe 2023 to 2033

The Europe primary cell culture market size surpassed USD 1.65 billion in 2023 and is projected to reach USD 5.38 billion by 2033.

Year Market Size (USD Billion)
2023 1.65
2024 1.87
2025 2.10
2026 2.37
2027 2.67
2028 3.01
2029 3.40
2030 3.83
2031 4.31
2032 4.86
2033 5.38

 

Primary Cell Culture Market Overview

The rise in chronic diseases such as cancer, infections, autoimmune disorders, cardiovascular diseases, diabetes mellitus, and nephrological diseases is mostly to blame for the market expansion. Because of the growth in research, primary cell cultures have been widely used. The American Cancer Society estimates that there will be 16.9 million cancer patients and survivors in 2020. 71.0 million persons worldwide have chronic hepatitis C infection, according to the WHO (2020). Consequently, the need for research into cutting-edge therapeutics is being driven by the increasing number of chronic ailments being identified, which is anticipated to accelerate market expansion in the next years.

The market for primary cell culture is expanding in part because primary cell cultures are being used for in-vitro testing and medication screening. These are produced from tissues, allowing researchers to examine the cellular structure in the in vivo setting and demonstrate how normally they operate. As a result, they are employed as model systems to research drug and toxin effects, aging processes, signaling investigations, metabolic processes, and cell biochemistry and physiology.

Primary Cell Culture Market Growth Factors

Demand for primary cell culture is rising as a result of expanding research into developing new treatments. The need for primary cell culture is also growing as a result of the study into the characterization and isolation of viruses. The market for primary cell culture products is being driven by growing academic tissue culture research activities worldwide in the field of life sciences. In addition, the primary cell culture product makers continue to benefit from the rising prevalence of chronic disorders such as diabetes mellitus, autoimmune diseases, cancer, chronic infections, nephrological diseases, and cardiovascular diseases. Additionally, the prevalence of cancer is continuously rising on a global scale.

Primary Cell Culture Market Scope

Report Coverage Details
Market Size in 2023 USD 7.03 Billion
Market Size by 2033 USD 21.51 Billion
Growth Rate from 2024 to 2033 CAGR of 11.81%
Largest Market North America
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Product, By Application, and By Cell Type
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa


Primary Cell Culture Market Dynamics

Drivers:

Increasing cancer research

9.6 million people died from cancer, which is now the biggest cause of mortality in the world. Primary cells play a significant role in this study since the frequency of this illness has increased, necessitating substantial research for diagnosis and therapy. These cells are excellent models for finding cancer biomarkers and testing medications. They are also utilized to comprehend the molecular mechanisms behind cellular communication. In cancer research, initial cells are frequently subjected to high chemicals, radiation doses, and viruses, which cause these cells to become cancer by introducing oncogenes and causing genetic abnormalities. This makes it possible to study the altered signaling pathways of malignant cells as well as the molecular-level process and the etiology of cancer.

Restraints:

Concerns regarding primary cell culture contamination

One of the most frequent issues in cell culture labs is primary cell culture contamination. Utilizing tainted cells puts cell physiology at peril, frequently yields inaccurate findings, or results in the loss of distinctive cell lines. In addition to slowing down cell metabolism, contamination in cell cultures may infect finished goods like vaccinations, which can completely ruin a batch. As a result, businesses restrict their funding for cell-based research and choose alternate techniques for drug screening.

Opportunities:

Advancing biomedical research using primary cells in 3D cultures

Due to their nearly exact resemblance to the original donor tissue, primary cells are thought to be more physiologically representative than cell lines. This makes it clearer that primary cells used in 3D cell structures are better adept than cell lines to create physiologically accurate representations of in vivo multicellular settings. Because they produce results that are more precise than those of conventional cell lines, primary cells are widely used in 3D cultures. For instance, primary hepatocytes grown in a monolayer on plastic undergo undifferentiation and pass away after four days.

Impact of COVID-19:

The COVID-19 epidemic is helping to fuel the expansion of the primary cell culture sector. Primary cell culture is being used more often by researchers to study the illness. Epithelium cell culture models that have been standardized and characterized are making it easier to comprehend how the coronavirus eroded the physical barrier. These models can assist in simulating the features and operations of the respiratory system, which might result in a breakthrough for the translation of a research finding into a medicinal application. Additionally, it has been demonstrated that the primary immune cell culture is highly helpful in the investigation of the immunological repertoire to generate antibodies and antigens for the COVID-19 virus. Researchers from the German Primate Centre in Gottingen discovered that the COVID-19 virus might prevent infection in lung cells by using TMPRSS2, a serine protease inhibitor. With the primary cell culture experiment, the findings have been confirmed.

Product Insights

The primary cell culture market was led by the reagents and supplements category, which also generated the most revenue at 36% in 2023. The segment's expansion is the result of its regular use in primary cell culture-based research and manufacture. Because primordial cells are naturally delicate, the reagents and supplements are thought to be essential for their development.

The creation of novel products like growth factors and cytokines is also a role in the segment's expansion. For instance, in October 2020, Safi Biosolutions, Inc. and iBio, Inc., a biotechnology business with headquarters in the United States, struck a strategic partnership to work together on the creation of cytokines and growth factors utilizing iBio's FastPharming System.

Applicational Insights

In 2023, the primary cell culture market was dominated by the vaccine manufacturing sector, which also had the biggest revenue share. This expansion can be attributed to the growing use of primary animal cultures for the viral generation that is used to create various vaccinations, including those for hepatitis B and measles. Additionally, this has reduced the costs related to using animal models for vaccination testing. Over the course of the projected period, the stem cell treatment market is anticipated to grow at a profitable CAGR. The expansion of the market is linked to scientists' increased interest in employing stem cells in various research initiatives. Researchers' perspectives on primary cells are being quickly altered by studies involving adult, induced, and embryonic stem cells. In addition, stem cell-based treatments have demonstrated considerable promise and potential in treating a variety of conditions, including diabetes, dentistry, ophthalmic illnesses, and neurodegenerative diseases. As a result, it is further projected that the market would be driven by the growing application of such therapies.

Cell Type Insights:

In 2023, the market for primary cell culture was dominated by the animal cells sector, which contributed 61% of total revenue. One of the main drivers of the market's expansion is the expanding use of primary cells of animal origin for the creation of vaccines. The creation of vaccinations against rabies, chickenpox, polio, measles, and hepatitis B has utilized animal-derived primary cultures.

Primary Cell Culture Market Share, By Cell Type, 2023 (%)

For the projection period, the human cells sector is anticipated to experience significant expansion. The increasing use of primary cultures made from human tissue for cancer research is largely to blame for the segment's rise. To enable the physiologically appropriate research of cancer, primary human cancer cells are obtained from a range of tissue types, including the brain, skeletal muscle, and connective tissue. These cultures can be used as a reliable tool for preclinical and clinical investigations in cancer research because they closely match the behavior and phenotype of cancer tissues.

Primary Cell Culture Market Recent Developments

  • In January 2021, Thermo Fisher Scientific Inc. introduced a groundbreaking medium designed for the cultivation of human T cells used in allogeneic cell therapies. The newly developed Gibco CTS OpTmizer Pro SFM is specifically designed to enhance the expansion of donor T cells, also known as lymphocytes. This innovative media option prioritizes the metabolism of healthy donors and offers a cost-effective solution for efficient production of cell-based treatments.
  • To aid in the discovery and development of new liver disease drugs, BioIVT (US) added high-purity Kupffer cells to their collection of human primary hepatic cells in May 2020.
  • HemaCare Corporation was purchased by Charles River Laboratories in January 2020. The scientific skills of Charles River will be enhanced as a result of this purchase in the quickly developing cell therapy market.
  • Monkey and rodent hepatocytes were introduced to Sekisui XenoTech, LLC's (US) proprietary CryostaX product range in September 2018.

Primary Cell Culture Market Companies

  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Lonza
  • Cell Biologics, Inc.
  • PromoCell GmbH
  • HemaCare Corporation
  • ZenBio, Inc.
  • STEMCELL Technologies, Inc.
  • Corning Incorporated
  • AllCells
  • American Type Culture Collection
  • Axol Bioscience Ltd.
  • iXCells Biotechnologies
  • Neuromics
  • StemExpress
  • BioIVT
  • ScienCell Research Laboratories, Inc.
  • PPA Research Group, Inc.
  • Creative Bioarray
  • BPS Bioscience, Inc.
  • Epithelix Sàrl
  • ReachBio LLC
  • AcceGen
  • Sekisui XenoTech, LLC
  • Biopredic International

Segment Covered in the Report:

By Product

  • Primary Cell
  • Reagents
  • Supplements
  • Media

By Application

  • Vaccine Production
  • Stem Cell Therapy
  • Cancer Research

By Cell Type

  • Animal Cells
  • Human Cells

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

The global primary cell culture market size was valued at USD 7.03 billion in 2023 and it is expected to reach around USD 21.51 billion by 2033.

The global primary cell culture market will register growth rate of 11.81% between 2024 and 2033.

The major players operating in the primary cell culture market are Thermo Fisher Scientific, Inc., Merck KGaA, Lonza, Cell Biologics, Inc., PromoCell GmbH, HemaCare Corporation, ZenBio, Inc., STEMCELL Technologies, Inc., Corning Incorporated, AllCells, American Type Culture Collection, Axol Bioscience Ltd., iXCells Biotechnologies, Neuromics, StemExpress, BioIVT, ScienCell Research Laboratories, Inc., PPA Research Group, Inc., Creative Bioarray, BPS Bioscience, Inc., Epithelix Sàrl, ReachBio LLC and Others.

The driving factors of the primary cell culture market are the increasing cancer research and increased vaccine production.

North America region will lead the global primary cell culture market during the forecast period 2024 to 2033.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Primary Cell Culture Market 

5.1. COVID-19 Landscape: Primary Cell Culture Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Primary Cell Culture Market, By Product

8.1. Primary Cell Culture Market, by Product, 2024-2033

8.1.1 Primary Cell

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Reagents

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Supplements

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Media

8.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Primary Cell Culture Market, By Application

9.1. Primary Cell Culture Market, by Application, 2024-2033

9.1.1. Vaccine Production

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Stem Cell Therapy

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Cancer Research

9.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Primary Cell Culture Market, By Cell Type 

10.1. Primary Cell Culture Market, by Cell Type, 2024-2033

10.1.1. Animal Cells

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Human Cells

10.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Primary Cell Culture Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.4.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.5.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.4.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.5.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.6.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.2.7.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.4.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.5.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.6.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.3.7.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.4.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.5.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.6.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Application (2021-2033)

11.4.7.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.4.3. Market Revenue and Forecast, by Cell Type (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Application (2021-2033)

11.5.5.3. Market Revenue and Forecast, by Cell Type (2021-2033)

Chapter 12. Company Profiles

12.1. Thermo Fisher Scientific, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Merck KGaA

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Lonza

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Cell Biologics, Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. PromoCell GmbH

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. HemaCare Corporation

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. ZenBio, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. STEMCELL Technologies, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Corning Incorporated

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. AllCells

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client